Rhythm Pharmaceuticals (RYTM) had the highest return in Q3 2022 by a mid-cap US stock, returning 500.5%.
| ASSET | QUARTER | % RETURN |
|---|---|---|
Rhythm Pharmaceuticals (RYTM) | Q3 2022 | 500.49% |
Akero Therapeutics (AKRO) | Q3 2022 | 251.76% |
Verona Pharma PLC ADR (VRNA) | Q3 2022 | 146.86% |
Enovix (ENVX) | Q3 2022 | 104.18% |
Dyne Therapeutics (DYN) | Q3 2022 | 84.59% |
Catalyst Pharmaceuticals (CPRX) | Q3 2022 | 83.55% |
89bio (ETNB) | Q3 2022 | 81.5% |
Calix (CALX) | Q3 2022 | 80.94% |
Applied Opt (AAOI) | Q3 2022 | 75.48% |
Cogent Biosciences (COGT) | Q3 2022 | 70.51% |
Xometry (XMTR) | Q3 2022 | 67.77% |
Wingstop (WING) | Q3 2022 | 66.86% |
International Seaways (INSW) | Q3 2022 | 66.56% |
Centrus Energy (LEU) | Q3 2022 | 65.58% |
Riot Blockchain (RIOT) | Q3 2022 | 65.33% |
Genius Sports (GENI) | Q3 2022 | 63.84% |
Applied Digital (APLD) | Q3 2022 | 58.88% |
Torm PLC Class A (TRMD) | Q3 2022 | 58.68% |
Fluence Energy (FLNC) | Q3 2022 | 54.39% |
Payoneer Global (PAYO) | Q3 2022 | 53.55% |
CommScope (COMM) | Q3 2022 | 52.74% |
Weatherford International (WFRD) | Q3 2022 | 52.38% |
Apellis Pharmaceuticals (APLS) | Q3 2022 | 50.57% |
Sarepta Therapeutics (SRPT) | Q3 2022 | 48.24% |
Extreme Networks (EXTR) | Q3 2022 | 48.02% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
